Zevra Therapeutics, Inc.
ZVRA
Positions held
Your positionsZVRA isn't in your positions.
Add it to see shares, cost, and P&L here.
Fundamentals
| Market cap | $653.22M | Enterprise value | $433.15M | Trailing P/E | 11.96 | Forward P/E | 10.22 |
| PEG | 10.67 | Price / book | 3.00 | Beta | 0.98 | Dividend yield | 0.00% |
| Revenue growth | 53.3% | Earnings growth | -88.4% | Gross margin | 95.5% | Operating margin | 42.3% |
| Profit margin | 42.8% | ROE | 34.8% | ROA | 8.7% | Debt / equity | 0.01 |
| Current ratio | 5.17 | Free cash flow | $48.38M | Analyst recommendation | strong_buy | Mean target | $25.00 |
| 52w high | $15.04 | 52w low | $8.01 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $39.7M | $36.2M | $34.1M | $26.1M | $25.9M | — |
| Op margin | 42.3% | 24.4% | 27.3% | 15.9% | -47.6% | — |
| Net income | $8.8M | $37.9M | $12.2M | -$0.5M | $74.7M | — |
| Gross margin | 96.2% | 94.8% | 95.5% | 95.2% | 52.2% | — |
| Gross profit | $38.1M | $34.3M | $32.6M | $24.8M | $13.5M | — |
| Operating income | $16.8M | $8.8M | $9.3M | $4.1M | -$12.3M | — |
- Revenue +10% vs prior quarter ($40M vs $36M).
- Gross margin 96.2% (was 94.8% prior quarter).
- Operating margin expanded to 42.3%.
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $106M | $23.6M | $27.5M | $10.2M | — |
| Op margin | -4.0% | -368.5% | -180.6% | -245.1% | — |
| Net income | $83.2M | -$106M | -$46.0M | -$26.8M | — |
| Gross margin | 84.5% | 68.6% | 92.1% | 97.8% | — |
| Gross profit | $90.0M | $16.2M | $25.3M | $9.9M | — |
| Operating income | -$4.2M | -$87.0M | -$49.6M | -$24.9M | — |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-09-02 · Zevra Therapeutics to Present at Upcoming Investor Conferences
2026-08-21 · Zevra Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
2026-08-17 · Zevra Therapeutics Insider Sold Shares Worth $474,774, According to a Recent SEC Filing
2026-08-07 · What Could Zevra Therapeutics (ZVRA) New NPC Data Mean For Its Europe Review?
2026-08-06 · Zevra Therapeutics Q2 Earnings Call Highlights
2026-08-06 · Zevra Therapeutics Inc (ZVRA) (Q2 2026) Earnings Call Highlights: Revenue Surges 53% as ...
2026-08-06 · Zevra Therapeutics (ZVRA) Q2 Earnings and Revenues Surpass Estimates
2026-08-05 · Zevra Therapeutics: Q2 Earnings Snapshot
2026-08-05 · Zevra Reports Second Quarter 2026 Financial Results and Corporate Update
2026-08-04 · Zevra Therapeutics to Present at the Canaccord Genuity Annual Growth Conference
Price (daily)
Full chart · RSI · MACD · patterns